ES2180665T3 - Uso de factor de celulas madre y de receptor soluble de interleuquina-6 para la expansion ex-vivo de celulas hematopoyeticas multipotenciales. - Google Patents

Uso de factor de celulas madre y de receptor soluble de interleuquina-6 para la expansion ex-vivo de celulas hematopoyeticas multipotenciales.

Info

Publication number
ES2180665T3
ES2180665T3 ES95942865T ES95942865T ES2180665T3 ES 2180665 T3 ES2180665 T3 ES 2180665T3 ES 95942865 T ES95942865 T ES 95942865T ES 95942865 T ES95942865 T ES 95942865T ES 2180665 T3 ES2180665 T3 ES 2180665T3
Authority
ES
Spain
Prior art keywords
multipotential
cell factor
interubain
mother cell
vivo expansion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95942865T
Other languages
English (en)
Inventor
Tatsutoshi Nakahata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tosoh Corp
Amgen Inc
Original Assignee
Tosoh Corp
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/340,559 external-priority patent/US5610056A/en
Application filed by Tosoh Corp, Amgen Inc filed Critical Tosoh Corp
Application granted granted Critical
Publication of ES2180665T3 publication Critical patent/ES2180665T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

EL FACTOR DE LAS CELULAS PLURIPOTENCIALES, EN COMBINACION CON EL RECEPTOR DE INTERLEUQUINA-6 SOLUBLE, INTERLEUQUINA-6, PARA SEÑALAR LA GP130, PROMUEVE LA PROLIFERACION, DIFERENCIACION Y MADURACION TERMINAL DE LAS CELULAS SANGUINEAS, A PARTIR DE CELULAS PLURIPOTENCIALES HEMATOPOYETICAS HUMANAS, NORMALES.
ES95942865T 1994-11-16 1995-11-16 Uso de factor de celulas madre y de receptor soluble de interleuquina-6 para la expansion ex-vivo de celulas hematopoyeticas multipotenciales. Expired - Lifetime ES2180665T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/340,559 US5610056A (en) 1994-11-16 1994-11-16 Use of stem cell factor interleukin-6 and soluble interleukin-6 receptor to induce the development of hematopoietic stem cells
US39314695A 1995-02-21 1995-02-21

Publications (1)

Publication Number Publication Date
ES2180665T3 true ES2180665T3 (es) 2003-02-16

Family

ID=26992162

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95942865T Expired - Lifetime ES2180665T3 (es) 1994-11-16 1995-11-16 Uso de factor de celulas madre y de receptor soluble de interleuquina-6 para la expansion ex-vivo de celulas hematopoyeticas multipotenciales.

Country Status (13)

Country Link
US (1) US5861315A (es)
EP (1) EP0793714B1 (es)
JP (1) JP3600244B2 (es)
CN (1) CN1170926C (es)
AT (1) ATE221118T1 (es)
AU (1) AU699479B2 (es)
CA (1) CA2198603C (es)
DE (1) DE69527540T2 (es)
DK (1) DK0793714T3 (es)
ES (1) ES2180665T3 (es)
MX (1) MX9701512A (es)
PT (1) PT793714E (es)
WO (1) WO1996015230A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2336637A1 (es) * 2009-11-02 2010-04-14 Banc De Sang I Teixits Procedimiento parala expansion indiferenciada u orientada a linaje mieloide de celulas madre hematopoyeticas procedentes de sangre de cordonumbilical, sangre periferica movilizada o medula osea.

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078224B1 (en) 1999-05-14 2006-07-18 Promega Corporation Cell concentration and lysate clearance using paramagnetic particles
US6582960B1 (en) * 1998-09-18 2003-06-24 Massachusetts Institute Of Technology Use of fibroblast growth factor 2 for expansion of chondrocytes and tissue engineering
MXPA03005014A (es) * 2000-12-06 2004-09-10 Robert J Hariri Metodo para recolectar celulas madres de la placenta.
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
AU2002251935B2 (en) 2001-02-14 2007-11-29 Celularity Inc. Post-partum mammalian placenta, its use and placental stem cells therefrom
EP2338983B1 (en) 2001-02-14 2015-10-07 Anthrogenesis Corporation Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
CA2442177A1 (en) 2001-03-29 2002-10-10 Ixion Biotechnology, Inc. Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway
EP1424389A4 (en) * 2001-08-07 2004-08-25 Kirin Brewery METHOD FOR PRODUCING HEMATOPOETIC STEM CELLS
US8021876B2 (en) * 2001-11-15 2011-09-20 Children's Medical Center Corporation Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
EP1482787A4 (en) * 2002-02-13 2006-02-15 Anthrogenesis Corp EMBRYONIC TYPE DERIVED STEM CELLS DERIVED FROM MAMMALIAN POST-PARTUM PLACENTA, USES THEREOF, AND METHODS OF TREATMENT BASED ON CELLS OF THIS TYPE
AU2003222043A1 (en) * 2002-03-18 2003-10-08 National Jewish Medical And Research Center Method for production of neutrophils and uses therefor
US20040161419A1 (en) * 2002-04-19 2004-08-19 Strom Stephen C. Placental stem cells and uses thereof
CA2483010A1 (en) * 2002-04-19 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Placental derived stem cells and uses thereof
US20040076620A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of repairing primate mammalian tissue
US20040044300A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
US20040042997A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of regenerating human tissue
US20040077985A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
US20040076605A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of regenerating human tissue
US20040043009A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of repairing primate mammalian tissue
EP1400587A1 (en) * 2002-09-19 2004-03-24 MainGen Biotechnologie GmbH Use of a fusion polypeptide for obtaining pluripotent non-embryonic stem cells
AU2003295444A1 (en) * 2002-11-15 2004-06-15 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
AU2003298775B2 (en) * 2002-11-26 2008-07-17 Anthrogenesis Corporation Cytotherapeutics, cytotherapeutic units and methods for treatments using them
NZ566132A (en) * 2003-02-13 2009-09-25 Anthrogenesis Corp Use of umbilical cord blood to treat inflammation, ParkinsonÆs disease or diabetes
GB0321337D0 (en) * 2003-09-11 2003-10-15 Massone Mobile Advertising Sys Method and system for distributing advertisements
US7829336B2 (en) * 2003-11-24 2010-11-09 The Rockefeller University Method for isolating a self-renewing, multipotent, slow-cycling cell
BRPI0417186A (pt) * 2003-12-02 2007-03-06 Celgene Corp método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica
NZ553695A (en) 2004-08-16 2009-10-30 Cellres Corp Pte Ltd Isolation of stem/progenitor cells from amniotic membrane of umbilical cord
US20060193839A1 (en) * 2005-02-28 2006-08-31 Donnie Rudd Method of providing readily available cellular material derived from peripheral blood, and a composition thereof
WO2007005613A2 (en) * 2005-07-01 2007-01-11 Promega Corporation Network of buoyant particles for biomolecule purification
EP1957633B1 (en) * 2005-10-13 2013-12-18 Anthrogenesis Corporation Immunomodulation using placental stem cells
WO2007070381A2 (en) 2005-12-09 2007-06-21 Promega Corporation Nucleic acid purification with a binding matrix
AU2006332679A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
WO2007102814A2 (en) * 2006-03-07 2007-09-13 Regenetech, Inc. Recombinant mammalian molecules and method for production thereof
JP2010518812A (ja) * 2007-02-12 2010-06-03 アンスロジェネシス コーポレーション 接着性胎盤幹細胞由来の肝細胞および軟骨細胞、ならびにｃｄ３４＋、ｃｄ４５−胎盤幹細胞の濃縮細胞集団
CN103356710A (zh) * 2007-02-12 2013-10-23 人类起源公司 利用胎盘干细胞治疗炎性疾病
US20100172830A1 (en) * 2007-03-29 2010-07-08 Cellx Inc. Extraembryonic Tissue cells and method of use thereof
EP2607477B1 (en) 2007-05-03 2020-09-23 The Brigham and Women's Hospital, Inc. Multipotent stem cells and uses thereof
US8574567B2 (en) * 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
EP2203176B1 (en) 2007-09-28 2014-11-26 Anthrogenesis Corporation Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
AU2008325142A1 (en) * 2007-11-07 2009-05-14 Anthrogenesis Corporation Use of umbilical cord blood in the treatment of premature birth complications
US8039613B2 (en) 2009-08-28 2011-10-18 Promega Corporation Methods of purifying a nucleic acid and formulation and kit for use in performing such methods
US8222397B2 (en) * 2009-08-28 2012-07-17 Promega Corporation Methods of optimal purification of nucleic acids and kit for use in performing such methods
MX342995B (es) 2010-07-13 2016-10-21 Anthrogenesis Corp Métodos de generar células asesinas naturales.
US9725689B2 (en) 2010-10-08 2017-08-08 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
DK2714059T3 (en) 2011-06-01 2019-01-21 Celularity Inc TREATMENT OF PAIN WHEN USING PLACENT STAM CELLS
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
EP3622960A1 (en) 2013-02-05 2020-03-18 Celularity, Inc. Natural killer cells from placenta
EP3068867B1 (en) 2013-11-16 2018-04-18 Terumo BCT, Inc. Expanding cells in a bioreactor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP4314244B1 (en) 2021-03-23 2025-07-23 Terumo BCT, Inc. Cell capture and expansion
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
CN116622630A (zh) * 2023-06-20 2023-08-22 中国科学技术大学 用于诱导成红细胞终末分化的脱核阶段培养基、培养体系

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2168273T3 (es) * 1992-04-23 2002-06-16 Sloan Kettering Inst Cancer Ligando para el receptor c-kit y metodos de uso del mismo.
US5599703A (en) * 1993-10-28 1997-02-04 The United States Of America As Represented By The Secretary Of The Navy In vitro amplification/expansion of CD34+ stem and progenitor cells

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2336637A1 (es) * 2009-11-02 2010-04-14 Banc De Sang I Teixits Procedimiento parala expansion indiferenciada u orientada a linaje mieloide de celulas madre hematopoyeticas procedentes de sangre de cordonumbilical, sangre periferica movilizada o medula osea.
ES2336637B1 (es) * 2009-11-02 2011-01-21 Banc De Sang I Teixits Procedimiento parala expansion indiferenciada u orientada a linaje mieloide de celulas madre hematopoyeticas procedentes de sangre de cordonumbilical, sangre periferica movilizada o medula osea.

Also Published As

Publication number Publication date
DE69527540T2 (de) 2003-01-30
CN1224461A (zh) 1999-07-28
MX9701512A (es) 1997-05-31
CA2198603C (en) 2000-06-27
EP0793714A2 (en) 1997-09-10
JPH10509040A (ja) 1998-09-08
CA2198603A1 (en) 1996-05-23
DK0793714T3 (da) 2002-09-02
AU4407396A (en) 1996-06-06
ATE221118T1 (de) 2002-08-15
PT793714E (pt) 2002-12-31
JP3600244B2 (ja) 2004-12-15
EP0793714B1 (en) 2002-07-24
US5861315A (en) 1999-01-19
AU699479B2 (en) 1998-12-03
WO1996015230A2 (en) 1996-05-23
WO1996015230A3 (en) 1996-07-11
CN1170926C (zh) 2004-10-13
DE69527540D1 (de) 2002-08-29

Similar Documents

Publication Publication Date Title
MX9701512A (es) Uso del factor de celulas madre y receptor de interleucina-6 soluble para la expansion ex vivo de celulas multipotenciales hematopoyeticas.
IL128129A (en) Uses for human wnt polypeptides
ES2139574T3 (es) Nuevos gases propulsores y su uso en preparaciones medicas.
IT1200176B (it) Struttura per poltrone con sedile e schienale mobili, in particolare per uso odontoiatrico
MX9301753A (es) Generacion in vitro de celulas dentriticas humanas y utilizacion de las mismas.
ES2170096T3 (es) Uso de lineas celulares fetales neuroderivadas para terapia de trasplantes.
AU8676791A (en) Clip and osteosynthesis plate with dynamic compression and self-retention
ES2147720T3 (es) Factor de celulas madre.
DE69718053D1 (de) in vitro methoden und verwendung von pharmazeutische zusammensetzungen für die BEHANDLUNG VON INNENOHRHAARZELLEN
IT8423748A0 (it) Derivati polisostituiti di naftalene, relativo procedimento di preparazione e uso in campo farmaceutico e cosmetico.
NO864203D0 (no) Biologiske makromolekyler.
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
ATE357509T1 (de) Stimulierung von hämatopoietischen zellen im vitro
PT786002E (pt) Isoforma intracelular do antagonista do receptor da interleuquina-1
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
ES2140489T3 (es) Receptor de interferona soluble, su preparacion y su uso.
ATE432978T1 (de) T-zellaktivierung
IT1319275B1 (it) Uso del baclofen nel trattamento dell'astinenza da etanolo.
ES2183890T3 (es) Uso del factor de crecimiento de hepatocitos para in estimular la proliferacion y diferenciacion de celulas hematopoyeticas.
ES2107414T3 (es) Utilizacion de interferon-beta humano para la estimulacion de la eritropoyesis.
DK561888A (da) Titanoxid med stabiliserede egenskaber til anvendelse i katalysatorer og fremgangsmaade til fremstilling deraf
ES2126575T3 (es) Sacarosa-fosfato-sintasa (sps), su procedimiento de preparacion, su adnc, y utilizacion de adnc para modificar la expresion de sps en celulas vegetales.
IT9019107A0 (it) Procedimento per la preparazione di un diaframma completamente di carbonio da usare in apparecchiature acustiche
ATE40116T1 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
DE3879492D1 (de) Hexafluoroneopentyl alkohol, dessen derivate, fluorierte polymere und deren verwendung.